More endpoints met in Insmed's Phase III brensocatib trial

By Yahoo! Finance | Jul 3, 2024 at 12:41 PM EST

Insmed's Phase III ASPEN trial data reveals brensocatib's effectiveness in reducing lung function decline in bronchiectasis patients. Positive results support potential approval as a chronic treatment. Full data will be presented at the WBC in July 2024.

Did you find this insightful?

Bad

Just Okay

Amazing

We are preparing, please wait

New Alert

Select an alert type

Sentiment Spike

Send email alert if news sentiment changes significantly

Mentions Spike

Send email alert if has a surge in mentions

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.